682
Participants
Start Date
December 11, 2019
Primary Completion Date
May 28, 2020
Study Completion Date
July 13, 2020
Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.)
Topical treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA)
Topical treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)
Topical placebo to treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
Moore Clinical Research, Brandon
Moore Clinical Reseach, Tampa
FXM Research International, Belize City
Lead Sponsor
Collaborators (2)
Novum Pharmaceutical Research Services
INDUSTRY
ACM Global Laboratories
OTHER
Douglas Pharmaceuticals America Ltd
INDUSTRY